Atlas Trials

A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia

Clinical trial NCT03810183 · TERMINATED

Trial details

NCT number
NCT03810183
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Obstructive Pulmonary Disease
Start date
2019-05-21
Primary completion
2020-01-16
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.